ASBM Shares EU Physician Survey in Paris Michael Reilly, Executive Director of the Alliance for Safe Biologic Medicines, (ASBM) was featured as an expert panelist at the “Understanding Biologic Medicine: Science, Regulatory Policy and the Changing Dynamics of Biosimilars” event hosted by AbbVie on June 10th in Paris, France. The two-part event was webcast worldwide […]
ASBM Shares EU Physician Survey in Paris Michael Reilly, Executive Director of the Alliance for Safe Biologic Medicines, (ASBM) was featured as an expert panelist at the “Understanding Biologic Medicine: Science, Regulatory Policy and the Changing Dynamics of Biosimilars” event hosted by AbbVie on June 10th in Paris, France. The two-part event was webcast worldwide […]
GaBI Publishes ASBM Whitepaper on European Prescriber Survey On June 5, The Generics and Biosimilars Initiative Journal published a paper authored by ASBM’s Chairman Richard Dolinar, MD and its Executive Director Michael Reilly. The paper is based on data collected by ASBM for its 2013 survey of 470 prescribing physicians with clinical experience using biologics […]
GaBI Publishes ASBM Whitepaper on European Prescriber Survey On June 5, The Generics and Biosimilars Initiative Journal published a paper authored by ASBM’s Chairman Richard Dolinar, MD and its Executive Director Michael Reilly. The paper is based on data collected by ASBM for its 2013 survey of 470 prescribing physicians with clinical experience using biologics […]
Lawmaker Presses FDA for Guidance on Naming, Interchangeability Policies In a letter to FDA Commissioner Margaret Hamburg dated April 24, U.S. Rep. Anna Eshoo (D-CA) requested an update on FDA’s timeline for releasing guidance on biosimilar naming and interchangeability. “I believe clear and timely guidance on naming and interchangeability will allow both innovators and manufacturers […]
Lawmaker Presses FDA for Guidance on Naming, Interchangeability Policies In a letter to FDA Commissioner Margaret Hamburg dated April 24, U.S. Rep. Anna Eshoo (D-CA) requested an update on FDA’s timeline for releasing guidance on biosimilar naming and interchangeability. “I believe clear and timely guidance on naming and interchangeability will allow both innovators and manufacturers […]
ASBM Releases EU Physicians’ Survey in Brussels On March 18th in Brussels, the Alliance for Safe Biologic Medicines (ASBM) released the results of a survey of 470 European physicians from five countries regarding their prescribing habits and knowledge of biosimilar medicines. Participants in the survey included specialists in the fields of nephrology, rheumatology, dermatology, neurology, […]
ASBM Forum Brings Together Leaders on Biosimilars Issues in 2014 On February 25th, the Alliance for Safe Biologic Medicines (ASBM) held a forum to educate patient advocates, physician groups and members of its International Advisory Board on the complex issues related to biosimilars. The half-day forum entitled, “Ensuring Access to Safe Biosimilars: Policy Developments and […]
WHO’s Minutes Reflect INN Consideration of Separate Process for ‘Biologic Qualifiers’ for Biosimilars As reported in Inside Health Policy’s “WHO Mulls ‘Biological Qualifier,’ Separate from INN, For Biosimilars,” minutes from the meeting held this past October in Geneva reflect the serious examination by World Health Organization to create a system for unique names. ASBM chairman […]
ASBM Releases New European Survey in Dublin On November 22, ASBM Executive Director Michael Reilly presented preliminary findings of a new survey on European physicians’ views on biosimilar naming at the Drug Information Association (DIA) Biosimilars Workshop in Dublin, Ireland. The key findings showed that nonproprietary names matter to patient safety: 53% of physicians surveyed […]
